Results from Phase I Study of CB-839 in Combination with Everolimus or Cabozantinib in Patients with Renal Cell Carcinoma to be Presented at the 2018 American Society of Clinical Oncology Genitourinary Cancer Symposium
February 05, 2018 17:04 ET
|
Calithera Biosciences, Inc.
-Overall response rate of 40% and 100% disease control rate in advanced clear cell renal cell carcinoma patients treated with CB-839 plus Cabozantinib -Randomized placebo controlled CANTATA Phase 2...
Updated Results from Phase I Study of CB-839 in Combination with Paclitaxel in Patients with Triple Negative Breast Cancer to be Presented at the 2017 San Antonio Breast Cancer Symposium
December 05, 2017 08:00 ET
|
Calithera Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Dec. 05, 2017 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq:CALA), a clinical stage biotechnology company focused on discovering and developing novel small...
Initial Results from Phase 2 Study of CB-839 in Combination with Opdivo® (nivolumab) to be Presented at the Society for Immunotherapy of Cancer Meeting
November 07, 2017 08:01 ET
|
Calithera Biosciences, Inc.
Achieved confirmed responses in melanoma patients progressing on PD-1/PD-L1 therapy Expanding Bristol-Myers Squibb clinical collaboration SOUTH SAN FRANCISCO, Calif., Nov. 07, 2017 (GLOBE...
Calithera Biosciences Reports Third Quarter 2017 Financial Results and Recent Highlights
November 02, 2017 07:30 ET
|
Calithera Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 02, 2017 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq:CALA), a clinical-stage pharmaceutical company focused on discovering and developing novel small...
Calithera Announces First Patient Treated in Phase 1 Cohort of INCB01158 dosed in Combination with Keytruda
October 19, 2017 08:00 ET
|
Calithera Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Oct. 19, 2017 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq:CALA), a clinical-stage pharmaceutical company focused on discovering and developing novel small...
Calithera Biosciences Announces Appointment of Sumita Ray as General Counsel
October 03, 2017 08:00 ET
|
Calithera Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Oct. 03, 2017 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq:CALA), a clinical-stage pharmaceutical company focused on discovering and developing novel small...
Calithera Biosciences Appoints Blake Wise to Board of Directors
September 21, 2017 16:05 ET
|
Calithera Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Sept. 21, 2017 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq:CALA), a clinical-stage pharmaceutical company focused on discovering and developing novel small...
Calithera Biosciences to Present at the 2017 Cantor Fitzgerald Global Healthcare Conference and the Leerink Partners Immuno-Oncology Roundtable
September 20, 2017 08:00 ET
|
Calithera Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Sept. 20, 2017 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq:CALA), a clinical-stage pharmaceutical company focused on discovering and developing novel small...
Calithera Biosciences Announces CB-839 in Combination with Nivolumab Phase 1/2 Data Accepted for Oral Presentation at the Society for Immunotherapy of Cancer (SITC) 32nd Annual Meeting
September 19, 2017 15:11 ET
|
Calithera Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Sept. 19, 2017 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq:CALA), a clinical-stage pharmaceutical company focused on discovering and developing novel small...
Calithera Biosciences to Participate in the Citi 12th Annual Biotech Conference and the Wells Fargo Healthcare Conference
August 30, 2017 08:00 ET
|
Calithera Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Aug. 30, 2017 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq:CALA), a clinical-stage pharmaceutical company focused on discovering and developing novel small...